English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/4227
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Classical and novel roles of p53 and prospects for anticancer therapy

AutorFuster, José J. ; Sanz-González, Silvia M. ; Moll, Ute M.; Andrés, Vicente
Palabras clavep53
Genetically-engineered mice
Anticancer therapy
Fecha de publicaciónmay-2007
CitaciónTrends Mol Med 13 (5): 192-199
ResumenThe tumor suppressor p53 is a transcription factor that is frequently inactivated in human tumors. Therefore,restoring its function has been considered an attractive approach to restrain cancer. Typically, p53-dependent growth arrest, senescence and apoptosis of tumor cells have been attributed to transcriptional activity of nuclear p53. Notably, wild-type p53 gain-of-function enhances cancer resistance in the mouse, but it also accelerates aging in some models, possibly due to altered p53 activity. Therefore, the emerging evidence of mitochondrial transcription-independent activities of p53 has raised high expectations. Here, we review new developments in transcription-dependent and transcription-independent p53 functions, recent advances in targeting p53 for cancer treatment and the pitfalls of moving from the laboratory research to the clinical setting.
DescripciónThe definitive version is available at http://www.sciencedirect.com/science/journal/14714914
Versión del editorhttp://dx.doi.org/10.1016/j.molmed.2007.03.002
Aparece en las colecciones: (IBV) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Trends Mol Med 013-00192.pdf1,64 MBAdobe PDFVista previa
Mostrar el registro completo

Artículos relacionados:

NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.